Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Apple
AAPL
|
+$763M |
| 2 |
Amazon
AMZN
|
+$688M |
| 3 |
TSMC
TSM
|
+$562M |
| 4 |
Tesla
TSLA
|
+$419M |
| 5 |
Johnson & Johnson
JNJ
|
+$398M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
Novo Nordisk
NVO
|
+$366M |
| 4 |
JPMorgan Chase
JPM
|
+$335M |
| 5 |
ASML
ASML
|
+$325M |
Sector Composition
| 1 | Healthcare | 20.8% |
| 2 | Technology | 15.52% |
| 3 | Consumer Discretionary | 11.85% |
| 4 | Consumer Staples | 10.11% |
| 5 | Financials | 9.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3476
Microvision
MVIS
$343M
| $169K | ﹤0.01% |
+71,961
| New | +$169K |
|
|
GLDG
3477
GoldMining Inc
GLDG
$235M
| $168K | ﹤0.01% |
148,500
+20,800
| +16% | +$23.5K |
|
3478
Gray Media, Inc. Class A
GTN.A
$1.01B
| $168K | ﹤0.01% |
15,400
-1,600
| -9% | -$17.5K |
|
3479
United States Antimony
UAMY
$613M
| $168K | ﹤0.01% |
344,469
+15,370
| +5% | +$7.5K |
|
3480
BlackSky Technology
BKSY
$684M
| $167K | ﹤0.01% |
13,563
+5,763
| +74% | +$71K |
|
|
PPTA
3481
Perpetua Resources
PPTA
$1.86B
| $167K | ﹤0.01% |
57,214
+38,414
| +204% | +$112K |
|
|
SSY
3482
DELISTED
SunLink Health Systems
SSY
| $167K | ﹤0.01% |
274,478
-10,900
| -4% | -$6.63K |
|
|
ICVX
3483
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $167K | ﹤0.01% |
21,000
+5,900
| +39% | +$46.9K |
|
|
EMX
3484
EMX Royalty
EMX
$456M
| $166K | ﹤0.01% |
+87,719
| New | +$166K |
|
3485
2x Long VIX Futures ETF
UVIX
$425M
| $166K | ﹤0.01% |
+57
| New | +$166K |
|
3486
Quantum Corp
QMCO
$98M
| $165K | ﹤0.01% |
7,591
+2,388
| +46% | +$51.9K |
|
3487
TRX Gold Corp
TRX
$144M
| $164K | ﹤0.01% |
485,947
+196,054
| +68% | +$66.2K |
|
|
ITRG
3488
Integra Resources
ITRG
$453M
| $163K | ﹤0.01% |
103,240
-23,920
| -19% | -$37.8K |
|
|
SUNL
3489
DELISTED
Sunlight Financial Holdings, Inc.
SUNL
| $161K | ﹤0.01% |
6,255
-520
| -8% | -$13.4K |
|
3490
Werewolf Therapeutics
HOWL
$65.4M
| $160K | ﹤0.01% |
78,223
+59,923
| +327% | +$123K |
|
3491
Vinci Compass Investments Ltd. Class A Common Shares
VINP
$634M
| $160K | ﹤0.01% |
17,732
+900
| +5% | +$8.12K |
|
3492
Fortress Biotech
FBIO
$116M
| $159K | ﹤0.01% |
16,220
-13,153
| -45% | -$129K |
|
|
PATI
3493
DELISTED
Patriot Transportation Holding, Inc. Common Stock
PATI
| $159K | ﹤0.01% |
22,609
-1,100
| -5% | -$7.74K |
|
|
VIVS
3494
VivoSim Labs, Inc. Common Stock
VIVS
$10.9M
| $158K | ﹤0.01% |
9,338
-653
| -7% | -$11K |
|
3495
Daxor
DXR
$58.1M
| $157K | ﹤0.01% |
17,121
+200
| +1% | +$1.83K |
|
3496
Axogen
AXGN
$755M
| $156K | ﹤0.01% |
15,600
+5,600
| +56% | +$56K |
|
|
BLPH
3497
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $155K | ﹤0.01% |
171,799
-24,392
| -12% | -$22K |
|
3498
Birks Group
BGI
$16.4M
| $154K | ﹤0.01% |
19,400
-10,200
| -34% | -$81K |
|
|
WKME
3499
DELISTED
WalkMe Ltd. Ordinary Shares
WKME
| $154K | ﹤0.01% |
13,800
+1,700
| +14% | +$19K |
|
3500
Amneal Pharmaceuticals
AMRX
$3.14B
| $152K | ﹤0.01% |
76,400
-65,500
| -46% | -$130K |
|